ChemoCentryx Inc. (NASDAQ:CCXI) shares saw an uptick in trading volume on Friday . 167,189 shares were traded during trading, an increase of 8% from the previous session’s volume of 154,404 shares.The stock last traded at $4.97 and had previously closed at $4.84.

A number of research firms recently issued reports on CCXI. Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a research report on Thursday, May 19th. JPMorgan Chase & Co. restated a “buy” rating and set a $11.00 target price on shares of ChemoCentryx in a research report on Tuesday, August 9th. Finally, Zacks Investment Research downgraded shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Monday, May 16th.

The stock’s market capitalization is $238.81 million. The firm has a 50-day moving average price of $4.58 and a 200 day moving average price of $3.84.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.